Propanc Biopharma, Inc. · NASDAQ:PPCB
Propanc Biopharma — Investor Presentation (September 2018)
32 slides from Propanc Biopharma's investor presentation, Sep 7, 2018
Slide 1: Annual NewsMakers in the Biotech Industry
25% Annual NewsMakers in the @® Propanc | Biotech Industry Biopharma, Inc. September 2018 OTCQB: PPCB
Slide 2: Forward Looking Statement
Forward Looking Statement Any statements set forth above that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations and involve certain risks and uncerta
Slide 3: Our aim is to prevent tumor recurrence and metastasis from solid tumors
Our aim is to prevent tumor recurrence and metastasis from solid tumors. ~80% of cancers are from solid tumors and metastasis is the main cause of patient death. Our unique patented approach is designed to target and eradicate cancer stem cells not killed by radiation or chemotherapy. Why? Cancer st
Slide 4: About Propanc
About Propan * Propanc is a biopharmaceutical company developing new cancer treatments for patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers. ¢ The Company has developed a formulation of anti-cancer compounds designed to control or prevent tumors from recurring
Slide 5: Slide 5
Slide 6: Are there natural elements in our body that help fight cancer?
Are there natural elements in our body that help fight cance: Yes: enzymes stimulate biological reactions in the body. Especially enzymes secreted by the pancreas, essential for digestion of proteins and fats. Pancreatic Enzyme Therapy: A story with promising PANCREATIC SECRETION: A Sacks © Trypsino
Slide 7: Mixture of two proenzymes, trypsinogen and chymotrypsinogen
Mixture of two proenzymes, trypsinogen (T) & chymotrypsinogen (C) from bovine pancreas. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include ovarian and colorectal cancers. Have also shown efficacy in pancreatic, kidney, breast, brain, prostate, lung, liver, uterine and s
Slide 8: Induces Cell Differentiation
Induces Cell (Caco2 calls untreated (a) and treat (b- ®. In@)asmerovs microvillicanbe seen. Pande (¢)2nd (6 shor tight Jonction (anew heads), desmosomes (Grrows)andincrementin alycoren Seposits (asters) PRP induces cell differentiation, which we believe converts cancerous cells into normal cells. Ev
Slide 9: In Vivo Efficacy, Mouse Pancreatic Tumor Cells in C57BL/6 Mice
In Vivo Efficacy, Mouse Pancreatic Tumor Cells in CS57BL/6 Mice, Day 26 Orthotropic Pancreatic Tumours Pan 02, N = 10 Control Group (PBS) 350 bad 6 & é a ® ¢ » @ q = 2 200 ' ° . . e 400 so a hY ae ° + There was significant (p<0.05) reduction in mean tumour weight in animals treated with high-dose (8
Slide 10: GLP 28-Day Repeat-Dose Toxicity Study
GLP 28-Day Repeat-Dose Toxicity Study + 28 day, repeat-dose, in vivo toxicity of Trypsinogen and Chymotrypsinogen A, 1:6 ratio, daily repeated intravenous tail vein injection in Sprague-Dawley rats, evaluated: VY Alldose levels well tolerated. Y Not associated with any morbidity or clinical signs of
Slide 11: Terminal patients administered suppository formulation
46 terminal patients administered suppository formulation containing trypsinogen and chymotrypsinogen. No severe, or even serious adverse events observed from treatment. 19 from 46 patients significantly exceeded life expectancy (41.3%). Mean survival (9.0 Mo.) significantly higher than mean life ex
Slide 12: A New Frontier: Anti-Cancer Stem Cell Therapy
A New Frontier Anti-Cancer Stem Cell Therapy @ Propanc OTCQB: PPCB sen
Slide 13: Cancer stem cells: they do not replicate
They do not replicate They are not killed by conventional therapies Tumor suppressor genes, like guardians, in a normal cell detect mutations and prevent malignancies, but are silenced in CSCs The EMT program is switched on, promoting metastasis, which is the main cause of patient death from cancer.
Slide 14: Epithelial Mesenchymal Transition (EMT)
Epithelial Mesenchymal Transition (EMT) ¢ EMT is a normal biological event during embryogenesis & organ development. ¢ Associated with wound healing & tissue repair. ¢ When turned on in CSCs, cancer cells lose contact with neighbouring cells and may potentially invade and metastasize, life threateni
Slide 15: PRP is a patented approach that we believe
PRP is a patented approach that we believe: Inhibits tumor metastasis and relapse. Complements conventional anti-cancer therapies. Is safe at specified dosages with minimal toxicity Is not cytotoxic
Slide 16: PRP Regulates the EMT
PRP Regulates the EMT PRP PROMOTES a ¢ Exerts a potent anti-EMT effect in CSCs @® Propanc
Slide 17: Pancreatic CSCs did not survive post PRP treatment
cpas MERGE Significant percentage of Pancreatic CSCs (BxPC3) did not survive post PRP treatment. Beeson (cD32e+CD44+CXCRA Highly significant because suppressing CSC’s reduces risk of tumor recurrence.
Slide 18: RAC1b gene and TGF-β pathway
* RACI gene involved in control of adhesion, motility and proliferative capacity of CSCs: * Hyperactivity detected in breast and pancreatic cancers. * Increases signals for TGF-8 pathway, a key marker in metastasis. * RACIb antagonises RAC1, thus modulates TGF-8 pathway. « PRP increases expression o
Slide 19: PRP reverses the EMT
We have demonstrated (in vitro & in vivo) that PRP dramatically reverses the EMT. By reversing the EMT, PRP: Stops tumor progression; Represses the CSC population. Potent indicators that PRP is an anti- CSC therapy.
Slide 20: Potential Over Competing Therapies
Potential Over Competing Therapies * No adverse effects observed. * Does not target replicating cells, so we believe it will not affect healthy cells and will suppress undesirable effects from cancer. * But, why not? Because PRP regulates expression of genes that triggers dominant pathways which are
Slide 21: Why We're Different
Why We’re Different ° “We have been working with cancer stem cells for several years, and our preclinical studies demonstrate that PRP has a significant effect on suppressing these cells, which are the maindrivers of cancers. 1am impressed in the lab, looking down on the microscope at pancreatic can
Slide 22: Corporate Strategy: Future Landscape
Corporate Strategy Future Landscape @ Propanc OTCQB: PPCB room
Slide 23: International R&D Partnerships
International R&D Partnerships UNIVERSITY OF BATH Joint IP ownership and Commercialization —— Agreement. Joint research collaboration: ® Universidad de Jaén Universidad de Granada . @ - New compound screening FIBAO - Translational research os en - Clinical development - Drug discovery oncology progr
Slide 24: Joint Scientific Publications
Joint Scientific Publications 1. Antitumour efficacy of chymotrypsinogen and trypsinogen, P. Hernandez, E. Lépez-Ruiz, M. A. Garcia, J. A. Marchal, J. Kenyon, M. Peran. 2. In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell different
Slide 25: Innovation & Intellectual Property
vation & Intellectual Property ¢ Four patent families covering several important discoveries regarding proenzymes and their anti-cancer effects. ¢ A further two patent applications in preparation covering composition of matter and method of use. ‘A pharmaceutical composition for treating USA, Europe
Slide 26: PRP Entering Pre-Commercialization Development Phase
PRP Entering Pre-Commercialization Development Phase * Scientific advice meetings with MHRA (UK), Apr 2016 and Mar 2018, for PRP, completed. * Orphan Drug Designation Status received from the FDA for the treatment of pancreatic cancer, 2017. * Current activities: 1. 28 day safety toxicokinetic study
Slide 27: Projected Development Timelines
Projected Development Timelines Jul/Aug Sep | Oct Nov Dec Jan Feb Mar Apr May Jun | Jul Aug |Sep Oct Nov Dec Jul (CTA Preparation Investigational Medicinal Product Dossier ((MPO) ‘Study Protocol (SP) ca Investigator’s Brochure (IB) ae ears CTA Submission CTA Approval Study Preparation (CRO Selection
Slide 28: Financial Plan
Financial Plan * Seeking $4M round to support IMP Manufacture and CTA for PRP. ¢ Initiate POP lresearch and drug discovery program. * Follow on round of $10M for early stage clinical development. General & Administrative: ise) Research & Development: 2.65 Total: $4.00M ® Propane amcreem
Slide 29: Drug Development & Clinical Expertise
Drug Development & Clinical Expertise Mr James Nathanielsz Chief Executive Officer + Director & CE.O, Oct ‘07. + 20 yrs. experience in R&D. ‘Manufacturing & Distribution, including 10 yrs. in oncology + Bachelor of Applied Science Giochemistry/ Applied Chemistry) & Master of Entrepreneurship & Innov
Slide 30: Medical and Scientific Advisory Board
Medical and Scientific Advisory Board Professor John Smyth Univ. of Edinburgh Professor Emeritus Medical Oncology & Honorary Assistant Principal Cancer Research Development, Univ. of Edinburgh Chair, Expert Advisory Group for Oncology & Hematology for the Commission of Medicines. Serves on the Exper
Slide 31: Current Company Profile & Comparisons
Current Company Profile & Comparisons Ticker: OTCQB:PPCB Status: Fully Reporting Shares (O/S): 124.244M Price*: $0.26 Mkt Cap*: $32.30M Ave Daily Vol. (30d): 10,387,549 52 Week Range: $0.77—0.004 Clinical Comparisons: OMED = $93.17M, STML = $478.35M, VSTM = $679.99M ® Propanc
Slide 32: Thank You!
Thank You! September 2018 James Nathanielsz Chief Executive Officer +61-414-835-002 jnathanielsz@propanc.com @ Prop. anc 302/6 Butler Street, Camberwell, Victoria, 3124, AUSTRALIA Biopharma, Inc. propanc.com
Propanc Biopharma — Investor Presentation (September 2018) on 6ix